H.C. Wainwright raised the firm’s price target on Zenas BioPharma (ZBIO) to $44 from $30 and keeps a Buy rating on the shares. The firm says obexelimab achieved the primary endpoint of 95% relative reduction in new gadolinium (Gd)-enhancing T1 lesions versus placebo in the Phase 2 MoonStone trial.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ZBIO:
- Midday Fly By: Novartis to buy Avidity, Keurig Dr Pepper beats expectations
- Zenas BioPharma Reports Positive Phase 2 Trial Results
- Zenas BioPharma says obexelimab met primary endpoint in Phase 2 MoonStone trial
- Zenas BioPharma files to sell 6.31M shares of common stock for holders
- Zenas BioPharma: Strategic Licensing and Clinical Advancements Justify Buy Rating